1. Effects of AIN457, a Fully Human Antibody to Interleukin- 17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis by Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold,, Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino,, C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk, David S. Chu, David Callanan, Quan Dong Nguyen,, Kristine Rose, Asifa Haider, and Franco Di Padova Sci Transl Med Volume 2(52):52ra72-52ra72 October 6, 2010 Published by AAAS

2. Fig. 1 Clinical response to AIN457 in patients with chronic plaque psoriasis. Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72 Published by AAAS

3. Fig. 2 Immunohistochemistry of skin biopsies: Representative immuno-costaining of CD3 and IL-17. Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72 Published by AAAS

4. Fig. 3 Gene expression changes in skin of patients with psoriasis treated with AIN457. Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72 Published by AAAS

5. Fig. 4 ACR20, DAS28, and CRP changes for a two-dose infusion regimen of AIN457 (10 mg/kg) versus placebo. Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72 Published by AAAS

6. Fig. 5 Vitreous haze (posterior segment uveitis) or anterior chamber cells (anterior uveitis) at week 8 versus week 0. Wolfgang Hueber et al., Sci Transl Med 2010;2:52ra72 Published by AAAS